Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision DC: Personalized Neoantigen Dendritic Cell Vaccine for High Risk TNBC
NCT06435351Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2024
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in triple-negative breast cancer (TNBC), sponsored by Moffitt Cancer Center. Primary endpoint: Percentage of patients enrolled who successfully undergo at least one vaccination at 3 years. Started Jun 2024; status: recruiting.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06435351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435351.